<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418457</url>
  </required_header>
  <id_info>
    <org_study_id>06-692</org_study_id>
    <nct_id>NCT00418457</nct_id>
  </id_info>
  <brief_title>Regional Anesthesia and Breast Cancer Recurrence</brief_title>
  <official_title>Regional Anesthesia and Breast Cancer Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center trial, Stage 1-3 patients having mastectomies or isolated lumpectomy
      with axillary node dissection will be randomly assigned to thoracic epidural or paravertebral
      anesthesia/analgesia, or to general anesthesia and morphine analgesia. Participants will be
      followed for up to 10 years to determine the rate of cancer recurrence or metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery is the primary and most effective treatment of breast cancer, but residual disease in
      the form of scattered micrometastases and tumor cells are usually unavoidable. Whether
      minimal residual disease results in clinical metastases is a function of host defense and
      tumor survival and growth. At least three perioperative factors shift the balance toward
      progression of minimal residual disease:

        1. Surgery per se depresses cell-mediated immunity, reduces concentrations of tumor-related
           anti-angiogenic factors (e.g., angiostatin and endostatin), increases concentrations of
           pro-angiogenic factors such as VEGF, and releases growth factors that promote local and
           distant growth of malignant tissue.

        2. Anesthesia impairs numerous immune functions, including those of neutrophils,
           macrophages, dendritic cells, T-cell, and natural killer cells.

        3. Opioid analgesics inhibit both cellular and humoral immune function in humans, increase
           angiogenesis, and promote breast tumor growth in rodents.

      However, regional analgesia attenuates or prevents each of these adverse effects by largely
      preventing the neuroendocrine surgical stress response, eliminating or reducing the need for
      general anesthesia, and minimizing opioid requirement. Animal studies indicate that regional
      anesthesia and optimum postoperative analgesia independently reduce the metastatic burden in
      animals inoculated with breast adenocarcinoma cells following surgery. Preliminary data in
      cancer patients are also consistent: paravertebral analgesia for breast cancer surgery
      reduced risk of recurrence or metastasis approximately four-fold (95% CI of estimated hazard
      ratio is 0.71 - 0.06) during a 2.5 to 4-year follow-up period compared to opioid analgesia.
      The investigators will thus test the hypothesis that recurrence after breast cancer surgery
      is lower with regional anesthesia/analgesia than with general anesthesia and opioid
      analgesia.

      In this multi-center trial, Stage 1-3 patients having mastectomies will be randomly assigned
      to thoracic epidural or paravertebral anesthesia/analgesia, or to general anesthesia and
      opioid analgesia. As with all time-to-event trials, interim and final analyses are based on
      the number of outcome events (recurrences in this case) rather than enrollment. The number of
      patients required is just an estimate and varies based on actual recurrence rates which in
      turn depend on patients' stage and grade, and ancillary treatments. There will be three
      evenly spaced interim analyses and a final analysis at 351 recurrences. Confirming our
      hypothesis will indicate that a minor modification to anesthetic management, one that can be
      implemented with little risk or cost, will reduce the risk of cancer recurrence — a
      complication that is often ultimately lethal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery</measure>
    <time_frame>up to 10 years</time_frame>
    <description>time to breast cancer recurrence from the end of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Experienced Post-Surgical Pain</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Brief Pain Inventory is used to evaluate with values of any pain vs. no pain (binary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Experienced Neuropathic Pain After Surgery</measure>
    <time_frame>6 month and 1 year</time_frame>
    <description>neuropathic pain is a binary outcome: any pain vs. no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 PCS Score</measure>
    <time_frame>6 month and 1 year</time_frame>
    <description>Physical and Mental Health Composite Scores (PCS &amp; MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 MCS Score</measure>
    <time_frame>6 month and 1 year</time_frame>
    <description>Physical and Mental Health Composite Scores (PCS &amp; MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2108</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>General anesthesia and opioid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General anesthesia followed by opioid administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional analgesia and propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General anesthesia and opioids</intervention_name>
    <description>General anesthesia, usually with sevoflurane, and opioid analgesia</description>
    <arm_group_label>General anesthesia and opioid</arm_group_label>
    <other_name>General anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regional analgesia and propofol</intervention_name>
    <description>Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
    <arm_group_label>Regional analgesia and propofol</arm_group_label>
    <other_name>Regional analgesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary breast cancer without known extension beyond the breast and axillary nodes
             (i.e. believed to be Tumor Stage 1-3, Nodes 0-2)

          -  Scheduled for unilateral or bilateral mastectomy with or without implant (isolated
             &quot;lumpectomy&quot; will not qualify)

          -  Isolated &quot;lumpectomy&quot; with axillary node dissection (anticipated removal of at least
             five nodes)

          -  Written informed consent, including willingness to be randomized to morphine or
             regional analgesia

        Exclusion Criteria:

          -  Previous surgery for breast cancer (except diagnostic biopsies)

          -  Inflammatory breast cancer

          -  Age &lt; 18 or &gt; 85 years old

          -  Scheduled free flap reconstruction

          -  ASA Physical Status ≥ 4

          -  Any contraindication to epidural or paravertebral anesthesia and analgesia (including
             coagulopathy, abnormal anatomy)

          -  Any contraindication to midazolam, propofol, sevoflurane, fentanyl, or morphine

          -  Other cancer not believed by the attending surgeon to be in long-term remission

          -  Systemic disease believed by the attending surgeon to present ≥ 25% two-year mortality
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel I Sessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>China</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://sciencedirect.com</url>
    <description>Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Author: Daniel I Sessler Contemporary Clinical Trials, Volume 29, Issue 4, July 2008, Pages 517-526</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <results_first_submitted>February 21, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>d sessler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Anesthesia; regional</keyword>
  <keyword>cancer recurrence</keyword>
  <keyword>Anesthesia; inhalational</keyword>
  <keyword>Analgesia; opioid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT00418457/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>General Anesthesia and Opioid</title>
          <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
        </group>
        <group group_id="P2">
          <title>Regional Analgesia and Propofol</title>
          <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1065"/>
                <participants group_id="P2" count="1043"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1065"/>
                <participants group_id="P2" count="1043"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>General Anesthesia and Opioid</title>
          <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
        </group>
        <group group_id="B2">
          <title>Regional Analgesia and Propofol</title>
          <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1065"/>
            <count group_id="B2" value="1043"/>
            <count group_id="B3" value="2108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="11"/>
                    <measurement group_id="B2" value="53" spread="12"/>
                    <measurement group_id="B3" value="53" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1065"/>
                    <measurement group_id="B2" value="1043"/>
                    <measurement group_id="B3" value="2108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="989"/>
                    <measurement group_id="B2" value="972"/>
                    <measurement group_id="B3" value="1961"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery</title>
        <description>time to breast cancer recurrence from the end of surgery.</description>
        <time_frame>up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>General Anesthesia and Opioid</title>
            <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
          </group>
          <group group_id="O2">
            <title>Regional Analgesia and Propofol</title>
            <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery</title>
          <description>time to breast cancer recurrence from the end of surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1065"/>
                <count group_id="O2" value="1043"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Experienced Post-Surgical Pain</title>
        <description>Brief Pain Inventory is used to evaluate with values of any pain vs. no pain (binary)</description>
        <time_frame>6 months and 1 year</time_frame>
        <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
        <group_list>
          <group group_id="O1">
            <title>General Anesthesia and Opioid</title>
            <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
          </group>
          <group group_id="O2">
            <title>Regional Analgesia and Propofol</title>
            <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced Post-Surgical Pain</title>
          <description>Brief Pain Inventory is used to evaluate with values of any pain vs. no pain (binary)</description>
          <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="856"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 6-month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="872"/>
                    <count group_id="O2" value="856"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                    <measurement group_id="O2" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="852"/>
                    <count group_id="O2" value="854"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>GEE</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Experienced Neuropathic Pain After Surgery</title>
        <description>neuropathic pain is a binary outcome: any pain vs. no pain</description>
        <time_frame>6 month and 1 year</time_frame>
        <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
        <group_list>
          <group group_id="O1">
            <title>General Anesthesia and Opioid</title>
            <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
          </group>
          <group group_id="O2">
            <title>Regional Analgesia and Propofol</title>
            <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced Neuropathic Pain After Surgery</title>
          <description>neuropathic pain is a binary outcome: any pain vs. no pain</description>
          <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="870"/>
                <count group_id="O2" value="859"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 6-month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="870"/>
                    <count group_id="O2" value="859"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="854"/>
                    <count group_id="O2" value="857"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>GEE</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-12 PCS Score</title>
        <description>Physical and Mental Health Composite Scores (PCS &amp; MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
        <time_frame>6 month and 1 year</time_frame>
        <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
        <group_list>
          <group group_id="O1">
            <title>General Anesthesia and Opioid</title>
            <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
          </group>
          <group group_id="O2">
            <title>Regional Analgesia and Propofol</title>
            <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>SF-12 PCS Score</title>
          <description>Physical and Mental Health Composite Scores (PCS &amp; MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
          <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="804"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 6-month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="804"/>
                    <count group_id="O2" value="788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="8.1"/>
                    <measurement group_id="O2" value="49.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="800"/>
                    <count group_id="O2" value="807"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="6.7"/>
                    <measurement group_id="O2" value="52.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-12 MCS Score</title>
        <description>Physical and Mental Health Composite Scores (PCS &amp; MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
        <time_frame>6 month and 1 year</time_frame>
        <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
        <group_list>
          <group group_id="O1">
            <title>General Anesthesia and Opioid</title>
            <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
          </group>
          <group group_id="O2">
            <title>Regional Analgesia and Propofol</title>
            <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>SF-12 MCS Score</title>
          <description>Physical and Mental Health Composite Scores (PCS &amp; MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
          <population>data was not available/collected for all participants due to lost follow up or miss phone call.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="804"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 6-month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="800"/>
                    <count group_id="O2" value="807"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" spread="8.6"/>
                    <measurement group_id="O2" value="48.7" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="804"/>
                    <count group_id="O2" value="788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="9.7"/>
                    <measurement group_id="O2" value="48.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>UP to 10 years After surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>General Anesthesia and Opioid</title>
          <description>General anesthesia followed by opioid administration
General anesthesia and opioids: General anesthesia, usually with sevoflurane, and opioid analgesia</description>
        </group>
        <group group_id="E2">
          <title>Regional Analgesia and Propofol</title>
          <description>Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
Regional analgesia and propofol: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1065"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1043"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1065"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1043"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1065"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1043"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Sessler, MD</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-4900</phone>
      <email>sessled@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

